Anthracycline and taxane-based was the most frequently used chemotherapy regimen: for 33 (71.7%) HER2+/HR+ patients, 21 (63.6%) HER2+/HR-negative patients, 58 (98.3%) HER2-negative/HR+ patients and 28 (93.3%) triple negative breast cancer patients. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.